Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
NCT ID: NCT01974167
Last Updated: 2014-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
400 participants
INTERVENTIONAL
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis
NCT02306187
Efficacy of Zoledronic Acid in Osteoporosis
NCT03183557
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
NCT05902078
Phase 3 Clinical Trial of Teriparatide in Japan
NCT00433160
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
NCT00504166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eldecalcitol group
Eldecalcitol 0.75 microgram once daily orally
Eldecalcitol
Eldecalcitol 0.75 microgram once daily orally
Alfacalcidol group
Alfacalcidol 1 microgram once daily orally
Alfacalcidol
Alfacalcidol 1 microgram once daily orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eldecalcitol
Eldecalcitol 0.75 microgram once daily orally
Alfacalcidol
Alfacalcidol 1 microgram once daily orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
(i) Have any existing insufficiency fracture (ii) %YAM \<80 (iii) Oral glucocorticoid daily dose \>= 5 mg prednisolone equivalent
* (2) Aged between 20 and 85 years (both inclusive) at consent
* (3) Patients who are able to walk without assistance
* (4) Provided consent to participate in the study
Exclusion Criteria
* (2) Have 3 or more vertebral fractures between L1 and L4.
* (3) Have 1 or more SQ grade 3 vertebral fractures, or 3 or more SQ grade 2 vertebral fractures.
* (4) Have received a bisphosphonate preparation for 2 weeks or longer within 6 months before the start of study treatment.
* (5) Have received a bisphosphonate preparation for 2 years or longer within 3 years before the start of study treatment.
* (6) Have received a parathyroid hormone preparation before the start of study treatment.
* (7) Have received one or more doses of an anti-RANKL (receptor activator of nuclear factor-kappa B ligand) antibody.
* (8) Have received one or more doses of an anti-sclerostin antibody or cathepsin K inhibitor.
* (9) Have received any other investigational product (including placebo) within 16 weeks before the start of study treatment in the present study.
* (10) Have received any of the following drugs that can affect bone metabolism within 8 weeks before the start of study treatment, with the exception of calcium preparations: (i) Bisphosphonates (ii) Active vitamin D preparations (including those for topical use) (iii) Selective estrogen receptor modulators (SERMs) (iv) Calcitonin preparations (v) Vitamin K2 preparations (vi) Ipriflavone preparations (vii) Reproductive hormone products (except those for vaginal use such as vaginal tablets and creams) (viii) Other drugs that can affect bone metabolism
* (11) Pregnant woman or woman who desires to become pregnant
* (12) Have corrected serum calcium \>= 10.4 mg/dL or \< 8.0 mg/dL at enrollment.
* (13) Have corrected urinary calcium \> 0.4 mg/dL GF at enrollment.
* (14) Have a past or current history of urinary calculus.
* (15) Have eGFR \< 30 mL/min/1.73 m2 at enrollment.
* (16) Have severe liver disease such as cirrhosis or severe heart disease such as severe cardiac failure.
* (17) Have active malignancy or received treatment for malignancy, including adjuvant therapy, within the past 3 years.
* (18) Have a history of hypersensitivity to eldecalcitol, alfacalcidol, or other vitamin D preparations.
* (19) Other persons judged by the investigator (or subinvestigator) to be inappropriate to participate in this study.
20 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
e-GLORIA trial Protocol Review Committee
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toshio Matsumoto
Role: STUDY_CHAIR
University of Tokushima
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nara Hospital Kinki University Faculty of Medicine
Ikoma, Nara, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMIN000011700
Identifier Type: REGISTRY
Identifier Source: secondary_id
2013/9/9 Ver1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.